UNIGE document Scientific Article
previous document  unige:112550  next document
add to browser collection
Title

Prérequis nécessaires pour la mise en place de protocoles de recherche clinique évaluant des thérapies cellulaires et géniques par lymphocytes T dotés de récepteur chimérique à l’antigène (CAR T-cells)

Authors
Yakoub-Agha, Ibrahim
Ferrand, Christophe
Ballot, Caroline
Castilla Llorente, Cristina
Deschamps, Marina
Gauthier, Jordan
Labalette, Myriam
show hidden authors show all authors [1 - 16]
Published in Bulletin du cancer. 2017, vol. 104, no. 12S, p. S43-S58
Abstract CAR T-cells are autologous or allogeneic human lymphocytes that are genetically engineered to express a chimeric antigen receptor targeting an antigen expressed on tumor cells such as CD19. CAR T-cells represent a new class of medicinal products, and belong to the broad category of Advanced Therapy Medicinal Products (ATMPs), as defined by EC Regulation 2007-1394. Specifically, they are categorized as gene therapy medicinal products. Although CAR T-cells are cellular therapies, the organization for manufacturing and delivery is far different from the one used to deliver hematopoietic cell grafts, for different reasons including their classification as medicinal products. Currently available clinical observations were mostly produced in the context of trials conducted either in the USA or in China. They demonstrate remarkable efficacy for patients presenting advanced or poor-prognosis hematological malignancies, however with severe side effects in a significant proportion of patients. Toxicities can and must be anticipated and dealt with in the context of a full coordination between the clinical cell therapy ward in charge of the patient, and the neighboring intensive care unit. The present workshop aimed at identifying prerequisites to be met in order for French hospitals to get efficiently organized and fulfill sponsors' expectations before initiation of clinical trials designed to investigate CAR T-cells.
Keywords ChimerismFranceHematologic Neoplasms/immunology/therapyHematopoietic Stem Cell Transplantation/methodsHospitalsHumansProgram DevelopmentReceptorsAntigenT-Cell/immunologySocietiesMedicalT-Lymphocytes/classification/immunology
Identifiers
PMID: 29174320
Note Sous titre: : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
Structures
Research group Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982)
Citation
(ISO format)
YAKOUB-AGHA, Ibrahim et al. Prérequis nécessaires pour la mise en place de protocoles de recherche clinique évaluant des thérapies cellulaires et géniques par lymphocytes T dotés de récepteur chimérique à l’antigène (CAR T-cells). In: Bulletin du cancer, 2017, vol. 104, n° 12S, p. S43-S58. https://archive-ouverte.unige.ch/unige:112550

72 hits

0 download

Update

Deposited on : 2019-01-04

Export document
Format :
Citation style :